There was no mighty roar, nor likely even contented purring, for oncology-focused Asian venture Aslan Pharmaceuticals Pte. Ltd. following its US initial public offering on the Nasdaq Global Market.
The Singapore-based venture set a public price of $7.03 per American Depositary Share in the offering of six million ADSs, each comprising five ordinary shares and all sold through ASLAN....